EA201490626A1 - Поэтапное дозирование клопидогрела - Google Patents

Поэтапное дозирование клопидогрела

Info

Publication number
EA201490626A1
EA201490626A1 EA201490626A EA201490626A EA201490626A1 EA 201490626 A1 EA201490626 A1 EA 201490626A1 EA 201490626 A EA201490626 A EA 201490626A EA 201490626 A EA201490626 A EA 201490626A EA 201490626 A1 EA201490626 A1 EA 201490626A1
Authority
EA
Eurasian Patent Office
Prior art keywords
gradual dosing
gradual
dosing
clopidogrel
stroke
Prior art date
Application number
EA201490626A
Other languages
English (en)
Inventor
Джон Р. Плачетка
Original Assignee
Поузен Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Поузен Инк. filed Critical Поузен Инк.
Publication of EA201490626A1 publication Critical patent/EA201490626A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение касается новых препаратов клопидогрела, обеспечивающих поэтапное/с интервалами высвобождение, для применения в качестве улучшенных антитромбоцитарных терапевтических средств при инсульте и сердечно-сосудистых показаниях.
EA201490626A 2011-09-14 2012-09-14 Поэтапное дозирование клопидогрела EA201490626A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161534648P 2011-09-14 2011-09-14
PCT/US2012/055550 WO2013040442A1 (en) 2011-09-14 2012-09-14 Phased dosing of clopidogrel

Publications (1)

Publication Number Publication Date
EA201490626A1 true EA201490626A1 (ru) 2014-08-29

Family

ID=47883794

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490626A EA201490626A1 (ru) 2011-09-14 2012-09-14 Поэтапное дозирование клопидогрела

Country Status (8)

Country Link
US (1) US20150024042A1 (ru)
EP (1) EP2755979A4 (ru)
CN (1) CN103917544A (ru)
BR (1) BR112014006124A2 (ru)
CA (1) CA2848756A1 (ru)
EA (1) EA201490626A1 (ru)
MX (1) MX2014003214A (ru)
WO (1) WO2013040442A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105218559A (zh) * 2015-10-21 2016-01-06 云南省药物研究所 一种稳定的非晶态硫酸氢氯吡格雷复合物
CN115980223B (zh) * 2022-12-29 2024-06-25 大连博源医学科技有限公司 一种用于检测血液中11-脱氢血栓烷b2的液相色谱-串联质谱方法和试剂盒

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7029701B2 (en) * 2000-09-11 2006-04-18 Andrx Pharmaceuticals, Llc Composition for the treatment and prevention of ischemic events
US20060210633A1 (en) * 2003-04-03 2006-09-21 Sun Pharmaceutical Industries Limited Programmed drug delivery system
US20060280795A1 (en) * 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
EA200800041A1 (ru) * 2005-06-13 2008-04-28 Элан Фарма Интернэшнл Лтд. Составы с наночастицами клопидогреля, содержащие комбинацию клопидогреля и аспирина
FR2887455B1 (fr) * 2005-06-28 2007-08-10 Sanofi Aventis Sa Formulation a liberation prolongee de principes actifs de medicaments
PL2007362T3 (pl) * 2006-04-04 2019-02-28 Kg Acquisition Llc Doustne postacie leku obejmujące czynnik przeciwpłytkowy i inhibitor kwasu
US20100145053A1 (en) * 2006-04-05 2010-06-10 Cadila Healthcare Limited Modified release clopidogrel formulation
WO2007122636A1 (en) * 2006-04-25 2007-11-01 Panacea Biotec Ltd Pharmaceutical compositions containing long chain fatty acids as excipients as well as a process for manufacturing the same
EP2255797A4 (en) * 2008-02-22 2011-09-07 Hanall Biopharma Co Ltd COMPOSITE PREPARATION
CN101703513B (zh) * 2009-11-10 2014-04-23 沈阳药科大学 阿司匹林和氯吡格雷或其药学上可接受的盐的复方缓释制剂
GB201003731D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery

Also Published As

Publication number Publication date
CN103917544A (zh) 2014-07-09
MX2014003214A (es) 2014-12-05
US20150024042A1 (en) 2015-01-22
EP2755979A4 (en) 2015-06-17
CA2848756A1 (en) 2013-03-21
EP2755979A1 (en) 2014-07-23
WO2013040442A1 (en) 2013-03-21
BR112014006124A2 (pt) 2017-04-11

Similar Documents

Publication Publication Date Title
UY34721A (es) Anticuerpos anti-hla-b*27 y usos de éstos.
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
IN2015DN00127A (ru)
HK1205141A1 (en) Anti-pcsk9 antibodies, formulations, dosing, and methods of use -pcsk9
AU340307S (en) Toy
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
BR112013025742A2 (pt) composição de vidros bioativos, sua utilização e respectivo métodos de obtenção.
BR112015009718A2 (pt) composição de matéria e artigo.
BR112014009802A2 (pt) composições de bismaleimida contendo nanossílica
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
SG11201502264SA (en) Stable metal compounds, their compositions and methods of their use
JO3154B1 (ar) عوامل مضادة لـ trpv4
MX2014005510A (es) Nuevas composiciones, produccion de las mismas y uso de las mismas para la produccion de poliamidas coladas.
BR112013030853A2 (pt) composição compreendendo extrato de pendúculo de caju.
UY4181Q (es) Taza
BR112014000255A2 (pt) composição de suplemento de ferro
IL233627A (en) Aldehydes as fragrances
BR112014028441A2 (pt) composição de proteína
UY34099A (es) ?composición de agentes de coalescencia?.
EA201490626A1 (ru) Поэтапное дозирование клопидогрела
EA201492280A1 (ru) Стабильный состав пексиганана
UY34613A (es) Composición de limpieza
FR2971397B1 (fr) Recifs artificiels notamment pour especes sedentaires
BR112015000468A2 (pt) composição detergente
BR112014013348A2 (pt) composição á base de ubidecarenona